Pharma — April 2023
-
Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical
https://www.proinvestor.com/investornyt/968639/satsuma-pharma-agrees-to-be-acquired-by-shin-nippon-biomedical -
Genentech : Tecentriq Combination Reduces Risk Of Cancer Returning In People With Liver Cancer https://www.proinvestor.com/investornyt/968640/genentech-tecentriq-combination-reduces-risk-of-cancer-returning-in-people-with-liver-cancer
-
AZN : IMFINZI-based Treatment Reduces Risk Of Disease Recurrence In Lung Cancer In Phase III Trial https://www.proinvestor.com/investornyt/968641/azn-imfinzi-based-treatment-reduces-risk-of-disease-recurrence-in-lung-cancer-in-phase-iii-trial
-
MorphoSys :
Long-term Data Show Prolonged, Durable Responses In DLBCL Patients Treated With Monjuvi https://www.proinvestor.com/investornyt/968633/morphosys-long-term-data-show-prolonged-durable-responses-in-dlbcl-patients-treated-with-monjuvi -
Lundbeck har milliardsællert inden for rækkevidde, vurderer børshus
https://www.proinvestor.com/investornyt/968646/lundbeck-har-milliardsaellert-inden-for-raekkevidde-vurderer-borshus -
GSK Plc: Gepotidacin Shows Non-inferiority To Nitrofurantoin In EAGLE-2 And EAGLE-3 Phase III Trials https://www.proinvestor.com/investornyt/968654/gsk-plc-gepotidacin-shows-non-inferiority-to-nitrofurantoin-in-eagle-2-and-eagle-3-phase-iii-trials
-
Inovio Presents Data From Phase 1b Trial With INO-4201 As Ebola Booster For RVSV-ZEBOV https://www.proinvestor.com/investornyt/968741/inovio-presents-data-from-phase-1b-trial-with-ino-4201-as-ebola-booster-for-rvsv-zebov
-
Is Johnson & Johnson a Buy After Its Proposed $8.9 Billion Talc Settlement? https://www.proinvestor.com/investornyt/968764/is-johnson-amp-johnson-a-buy-after-its-proposed-89-billion-talc-settlement
-
Dråbesalg styrker ALK-Abelló på toplinje og drift i første kvartal https://www.proinvestor.com/investornyt/969131/drabesalg-styrker-alk-abello-pa-toplinje-og-drift-i-forste-kvartal
-
HC Wainwright & Co. Reiterates Axsome Therapeutics (AXSM) Buy Recommendationhttps://www.proinvestor.com/investornyt/969108/hc-wainwright-amp-co-reiterates-axsome-therapeutics-axsm-buy-recommendation
-
Wells Fargo Initiates Coverage of Viridian Therapeutics (VRDN) with Overweight Recommendation https://www.proinvestor.com/investornyt/969111/wells-fargo-initiates-coverage-of-viridian-therapeutics-vrdn-with-overweight-recommendation
-
Stimen af opkøb fortsætter: GSK To Buy BELLUS Health In US$2.0 Bln Deal https://www.proinvestor.com/investornyt/969145/gsk-to-buy-bellus-health-in-us20-bln-deal
-
Basilea Provides Updated Timeline For NDA Submission For Antibiotic Ceftobiprole To FDA https://www.proinvestor.com/investornyt/969136/basilea-provides-updated-timeline-for-nda-submission-for-antibiotic-ceftobiprole-to-fda
-
FDA Approves Omisirge Cell Therapy For
Blood Cancers https://www.proinvestor.com/investornyt/969139/fda-approves-omisirge-cell-therapy-for-blood-cancers -
Teva, Alvotech's Humira biosimilar hit with second FDA rejection
https://firstwordpharma.com/story/5727774 -
FDA panel backs approval of Rexulti for Alzheimer's-related agitation https://firstwordpharma.com/story/5728435
-
Pyramid Bio bets on GeneQuantum's ADC candidate for over $1 billion
https://firstwordpharma.com/story/5727433 -
Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques https://firstwordpharma.com/story/5727905
-
AbbVie's Rinvoq nabs EU approval in Crohn's disease https://firstwordpharma.com/story/5728428
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind